CAS: 110958-19-5; (5R)-5-(Piperidine-1-Carbonyl)Pyrrolidin-2-One

上下游产品

CAS号110-89-4 六氢吡啶 | CAS号4042-36-8 d-焦谷氨酸 | CAS号575469-26-0 1-[(2R)-2-Pyrro...

D-焦谷氨酸置于对甲苯磺酸体系中,用 甲苯,乙腈 用作溶剂,化学反应 16.17H,反应生成法索西坦
参考文献:Synthesis Of Chiral Diamines Using Novel 2-Trichloromethyloxazolidin-4-One Precursors Derived From 5-Oxo-Proline And Proline
标题:Synthesis Of Chiral Diamines Using Novel 2-Trichloromethyloxazolidin-4-One Precursors Derived From 5-Oxo-Proline And Proline
摘要:Efficient Syntheses Of Chiral Vicinal Diamines Derived From (S)-Oxo-Proline And (S)-Proline Are Described. The Novel Diastereomerically Pure Precursor (2R,5S)-2-Trichloromethyl-1-Aza-3-Oxabicyclo-[3.3.0]-octan-4,8-Dione 3 And Its Enantiomer Are Readily Available By Reaction Of The Inexpensive Enantiomers Of 5-Oxo-Proline With Chloral. Compound 3 Reacts With Primary And Secondary Amines To Afford The 5-Oxo-Prolylamides 4 In Quantitative Yield. In Contrast,The (S)-Proline-Derived Precursor (2R,5S)-2-Trichloromethyl-1-Aza-3-Oxabicyclo[3.3.0]octan-4-One 6 Gave (S)-N-Formylprolylamides 9 And/or (S)-Prolylamides 8 Depending On The Reaction Conditions. Upon Reduction With Lialh4,Amides 4 And 9 Afforded The Proline-Derived (S)-2-(Alkylaminomethyl)Pyrrolidines 1 And (S)-N-Methyl-2-(Alkylaminomethyl)-Pyrrolidines 5 In 70-90% Yields. (C) 2002 Elsevier Science Ltd. All Rights Reserved.
Doi:10.1016/s0957-4166(02)00579-7

专利信息

专利号:US-2009176740-A1
优先权日:2007-11-30
标题:Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine
发明人：PHILLIPS II DAUGLAS JAMES
权利人:PHILLIPS II DAUGLAS JAMES
摘要:Aniracetam (1-[(4-methoxybenzoyl)]-2-pyrrolidinone) is co-administered with the acetylcholine precursor 1-alpha glycerylphosphorylcholine (Alpha GPC, choline alfoscerate, choline alphoscerate) to potentiate cognition enhancing effects in healthy subjects and patients suffering from neurological conditions including Alzheimer's Disease (AD), attention deficit disorder (ADD), Parkinson's Disease, schizophrenia, vascular dementia, post stroke aphasia, anxiety disorders, cerebral atrophy, chronic alcoholism, Down syndrome, dyslexia, and various other neurodegenerative conditions. The co-administration of aniracetam (and other racetam derivatives including oxiracetam) with the acetylcholine precursor 1-alpha glycerylphosphorylcholine decreases negative side-effects such as severe headaches while increasing the synthesis and release of the neurotransmitters acetylcholine and glutamate to facilitate proper brain functioning.